383 related articles for article (PubMed ID: 27719640)
21. Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer.
Nelson N; Szekeres K; Iclozan C; Rivera IO; McGill A; Johnson G; Nwogu O; Ghansah T
PLoS One; 2017; 12(2):e0170197. PubMed ID: 28152014
[TBL] [Abstract][Full Text] [Related]
22. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
23. Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach.
Borgo C; Cesaro L; Hirota T; Kuwata K; D'Amore C; Ruppert T; Blatnik R; Salvi M; Pinna LA
Eur J Med Chem; 2021 Mar; 214():113217. PubMed ID: 33548633
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Ge Z; Song C; Ding Y; Tan BH; Desai D; Sharma A; Gowda R; Yue F; Huang S; Spiegelman V; Payne JL; Reeves ME; Iyer S; Dhanyamraju PK; Imamura Y; Bogush D; Bamme Y; Yang Y; Soliman M; Kane S; Dovat E; Schramm J; Hu T; McGrath M; Chroneos ZC; Payne KJ; Gowda C; Dovat S
Leukemia; 2021 May; 35(5):1267-1278. PubMed ID: 33531656
[TBL] [Abstract][Full Text] [Related]
25. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
Chen H; Chen F; Liu N; Wang X; Gou S
Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic targeting of CK2 in acute and chronic leukemias.
Buontempo F; McCubrey JA; Orsini E; Ruzzene M; Cappellini A; Lonetti A; Evangelisti C; Chiarini F; Evangelisti C; Barata JT; Martelli AM
Leukemia; 2018 Jan; 32(1):1-10. PubMed ID: 28951560
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase CK2 inhibitors: emerging anticancer therapeutic agents?
Bortolato A; Cozza G; Moro S
Anticancer Agents Med Chem; 2008 Oct; 8(7):798-806. PubMed ID: 18855581
[TBL] [Abstract][Full Text] [Related]
29. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
Chon HJ; Bae KJ; Lee Y; Kim J
Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
[TBL] [Abstract][Full Text] [Related]
30. Kinase CK2 inhibition: an update.
Cozza G; Pinna LA; Moro S
Curr Med Chem; 2013; 20(5):671-93. PubMed ID: 23210774
[TBL] [Abstract][Full Text] [Related]
31. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
Battistutta R
Cell Mol Life Sci; 2009 Jun; 66(11-12):1868-89. PubMed ID: 19387547
[TBL] [Abstract][Full Text] [Related]
32. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
Gyenis L; Turowec JP; Bretner M; Litchfield DW
Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
[TBL] [Abstract][Full Text] [Related]
33. Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management.
Lian H; Su M; Zhu Y; Zhou Y; Soomro SH; Fu H
Asian Pac J Cancer Prev; 2019 Jan; 20(1):23-32. PubMed ID: 30677865
[TBL] [Abstract][Full Text] [Related]
34. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
35. Small molecule modulators targeting protein kinase CK1 and CK2.
Qiao Y; Chen T; Yang H; Chen Y; Lin H; Qu W; Feng F; Liu W; Guo Q; Liu Z; Sun H
Eur J Med Chem; 2019 Nov; 181():111581. PubMed ID: 31400711
[TBL] [Abstract][Full Text] [Related]
36. Anti-androgen receptor activity of apoptotic CK2 inhibitor CX4945 in human prostate cancer LNCap cells.
Ryu BJ; Baek SH; Kim J; Bae SJ; Chang SY; Heo JN; Lee H; Lee SY; Kim SH
Bioorg Med Chem Lett; 2012 Sep; 22(17):5470-4. PubMed ID: 22832316
[TBL] [Abstract][Full Text] [Related]
37. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
[TBL] [Abstract][Full Text] [Related]
38. Effect of Simultaneous Inhibition of Protein Kinase CK2 and Thymidylate Synthase in Leukemia and Breast Cancer Cells.
Wińska P; Skierka K; Łukowska-Chojnacka E; Koronkiewicz M; Cieśla J; Bretner M
Anticancer Res; 2018 Aug; 38(8):4617-4627. PubMed ID: 30061228
[TBL] [Abstract][Full Text] [Related]
39. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
40. CK2 inhibitor CX4945 induces sequential inactivation of proteins in the signaling pathways related with cell migration and suppresses metastasis of A549 human lung cancer cells.
Ku MJ; Park JW; Ryu BJ; Son YJ; Kim SH; Lee SY
Bioorg Med Chem Lett; 2013 Oct; 23(20):5609-13. PubMed ID: 24012124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]